OptimizeRx OPRX Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by OptimizeRx in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent.
The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about OptimizeRx's allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OptimizeRx's allowance for doubtful accounts receivable (current)?
- OptimizeRx (OPRX) reported allowance for doubtful accounts receivable (current) of $260K in Q1 2026.
- How has OptimizeRx's allowance for doubtful accounts receivable (current) changed year-over-year?
- OptimizeRx's allowance for doubtful accounts receivable (current) decreased by 22.4% year-over-year, from $335K to $260K.
- What is the long-term trend for OptimizeRx's allowance for doubtful accounts receivable (current)?
- Over 5 years (2020 to 2025), OptimizeRx's allowance for doubtful accounts receivable (current) has grown at a 10.5% compound annual growth rate (CAGR), from $158.16K to $260K.
- What does allowance for doubtful accounts receivable (current) mean?
- This is the valuation allowance for current receivables that are considered uncollectible due to disputes, bankruptcy, or other non-payment issues. It serves as a buffer against potential losses from customer defaults. It is a critical indicator of the health of the company's accounts receivable portfolio.